ARS Pharmaceuticals, Inc. — Director's Dealing 2023

Sep 6, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2023-09-01

Reporting Person: Shawver Laura (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-09-01	Common Stock	M	2997	$1.27	Acquired	213343	Direct
2023-09-01	Common Stock	M	97003	$1.27	Acquired	310346	Direct
2023-09-01	Common Stock	S	100000	$7.7052	Disposed	210346	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-09-01	Stock Option (Right to Buy)	$1.27	M	2997	Disposed	2030-04-28	Common Stock (2997)	Direct
2023-09-01	Stock Option (Right to Buy)	$1.27	M	97003	Disposed	2030-04-28	Common Stock (97003)	Direct

Footnotes

F1: The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2022.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.24 to $8.00, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein.

F3: Immediately exercisable.